Clinical Trials
52 trialsThalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Selinexor in Combination With Immunomodulator ļ¼Thalidomide/Pomalidomide/Lenalidomideļ¼in RRMM
Shanghai Changzheng Hospital
Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
Fujian Cancer Hospital
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
Sichuan University
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
Sun Yat-sen University
Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions
Shanghai Chest Hospital
Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
Guangdong Provincial People's Hospital
TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL
Institute of Hematology & Blood Diseases Hospital, China
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)
Qilu Hospital of Shandong University
The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol
Shenzhen Fifth People's Hospital
Myeloma XI
University of Leeds
Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma
National University Hospital, Singapore
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide
Fujian Cancer Hospital
BOMB-THROW
Seoul National University Hospital
CTd
Jinling Hospital, China
Thalidomide Maintenance Treatment in DLBCL
Nanfang Hospital, Southern Medical University
Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors
Haihe Biopharma Co., Ltd.
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
ChineseAMS
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
ChineseAMS
Conmana Combined With Thalidomide to Treat NSCLC
Henan Provincial People's Hospital
Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical
The First People's Hospital of Hefei
Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer
Changzhou No.2 People's Hospital
Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer
Zhejiang Cancer Hospital
MUKsix
University of Leeds
HLJDT-2016
Wuhan University
ITAGC
Zhengzhou University
Gefitinib Combined With Thalidomide to Treat NSCLC
Shaanxi Provincial People's Hospital
Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma
National Cancer Institute (NCI)
Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma
National Cancer Institute (NCI)
Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma
The First Affiliated Hospital of Xiamen University
Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years
Grupo de Estudos Multicentricos em Onco-Hematologia
KMM-97
Chonnam National University Hospital
Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma
Fudan University
Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Second Military Medical University
Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma
University Hospital, Bonn
UFUR
National Cheng-Kung University Hospital
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
National Cancer Institute (NCI)
LDT-RFA
Sun Yat-sen University
TCD Followed by autoSCT for Newly Diagnosed MM Patients
Korean Multiple Myeloma Working Party
Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma
University of Zurich
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Korean Multiple Myeloma Working Party
Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma
National Taiwan University Hospital